Clinical trials of antithrombotic therapy for peripheral artery disease (PAD)
| Therapy | Trial, date (agent) | |
|---|---|---|
| Symptomatic PAD | Single agent | CAPRIE 1996 (clopidogrel vs placebo)9 |
| CLIPS 2007 (ASA vs placebo)10 | ||
| EUCLID 2016 (ticagrelor vs clopidogrel)11 | ||
| Dual antiplatelet | CHARISMA 2009 (clopidogrel + ASA vs ASA)12 | |
| PLATO 2015 (ticagrelor + ASA vs clopidogrel + ASA)13 | ||
| PEGASUS-TIMI 54 2016 (ticagrelor + ASA vs ASA)14 | ||
| PRODIGY 2016 (clopidogrel + ASA for 24M vs 6M)15 | ||
| DAPT 2017 (P2Y12 inhibitor + ASA for 30M vs 12M)16 | ||
| PAR-1 antagonist | TRA2 P-TIMI 50 2013 (vorapaxar vs placebo)17 | |
| TRACER 2014 (vorapaxar vs placebo)18 | ||
| Anticoagulation | WAVE 2007 (warfarin + antiplatelet vs antiplatelet)19 | |
| COMPASS 2017 (rivaroxaban + ASA vs ASA)20 | ||
| Asymptomatic PAD | POPADAD 2008 (ASA vs placebo)21 | |
| AAA 2010 (ASA vs placebo)22 | ||
| Revascularization for PAD | Surgical | Dutch BOA 2000 (anticoagulation vs ASA)23 |
| CASPAR 2010 (clopidogrel + ASA vs ASA)24 | ||
| Endovascular | MIRROR 2012 (clopidogrel + ASA vs placebo)25 |
AAA = Aspirin for Asymptomatic Atherosclerosis; ASA = acetylsalicylic acid; BOA = Bypass Oral anticoagulants or Aspirin; CAPRIE = Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events; CASPAR = Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease; CHARISMA = Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; CLIPS = Critical Leg Ischaemia Prevention Study; COMPASS = Cardiovascular Outcomes for People Using Anticoagulation Strategies; DAPT = dual antiplatelet therapy; EUCLID = Examining Use of Ticagrelor in Peripheral Artery Disease; M = months; MIRROR = Management of Peripheral Arterial Interventions With Mono or Dual Antiplatelet Therapy; PAR = protease-activated receptor; PEGASUS-TIMI 54 = Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54; PLATO = Study of Platelet Inhibition and Patient Outcomes; POPADAD = Prevention of Progression of Arterial Disease and Diabetes; PRODIGY = Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; TRA2 P-TIMI 50 = Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–Thrombolysis In Myocardial Infarction 50; TRACER = Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome; WAVE = Warfarin Antiplatelet Vascular Evaluation
Source: Data from reference 8.